Intellia Therapeutics, INC Form 4 insider transactions

Intellia Therapeutics, Inc. Director Jesse Goodman reported the acquisition of 8,000 restricted stock units and 11,450 stock options as part of compensation on June 11, 2025.

Intellia Therapeutics, Inc. Director Brian Goff has reported the acquisition of 8,000 restricted stock units and 11,450 stock options, granted as part of his compensation, effective June 11, 2025.

Intellia Therapeutics, Inc. Director Muna Bhanji was granted 8,000 restricted stock units and options to purchase 11,450 shares of common stock, as disclosed in a recent SEC Form 4 filing.

Intellia Therapeutics, Inc. Director William J. Chase reported the acquisition of 8,000 restricted stock units and 11,450 stock options on June 11, 2025, increasing his direct beneficial ownership.

Intellia Therapeutics, Inc. Director Fred E. Cohen was granted 8,000 restricted stock units and options to purchase 11,450 shares of common stock on June 11, 2025.

Director Muna Bhanji of Intellia Therapeutics sold 265 shares of common stock on April 29, 2025, at a price of $8.5 per share, according to a Form 4 filing with the SEC.

Eliana Clark, EVP and Chief Technical Officer of Intellia Therapeutics, reports acquisition of stock options and restricted stock units, as well as a sale of shares to cover tax obligations.

Intellia Therapeutics CEO John M. Leonard reports acquisition of common stock and stock options, signaling potential confidence in the company's future.

EVP and CFO of Intellia Therapeutics, Edward J. Dulac III, reports acquisition of restricted stock units and stock options, as well as disposal of common stock.

Michael P. Dube, VP, Chief Accounting Officer of Intellia Therapeutics, reports acquiring 14,000 shares of common stock on March 1, 2025.

David Lebwohl, EVP and Chief Medical Officer of Intellia Therapeutics, reports the acquisition of restricted stock units and stock options.

EVP and Chief Scientific Officer of Intellia Therapeutics, Birgit Schultes, reports acquisition of restricted stock units and stock options.

EVP and General Counsel of Intellia Therapeutics, James Basta, reports acquisition of stock options and restricted stock units, along with a sale of shares to cover tax obligations.

Muna Bhanji, a director at Intellia Therapeutics, sold 265 shares of common stock at $9.97 per share under a pre-arranged 10b5-1 trading plan.

Michael P. Dube, VP and Chief Accounting Officer of Intellia Therapeutics, sold 1,372 shares of common stock on January 3, 2025, to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs).

James Basta, EVP and General Counsel of Intellia Therapeutics, sold 7,074 shares of common stock on January 3, 2025, to cover tax obligations related to vesting RSUs.

David Lebwohl, EVP and Chief Medical Officer at Intellia Therapeutics, sold 9,557 shares of common stock to cover tax obligations related to vesting RSUs.

Intellia Therapeutics' EVP, Chief Business Officer, Derek Hicks, sold 6,502 shares of common stock to cover tax obligations related to vesting of restricted stock units.

Intellia Therapeutics CEO John Leonard sold shares to cover tax obligations related to vesting RSUs, while also reporting shares held indirectly through a trust.

Laura Sepp-Lorenzino, EVP and Chief Scientific Officer of Intellia Therapeutics, sold shares to cover tax obligations arising from vesting RSUs.

Eliana Clark, EVP and Chief Technical Officer of Intellia Therapeutics, reports the sale of shares to cover tax obligations related to RSU vesting and shares acquired under the employee stock purchase plan.

David Lebwohl, EVP and Chief Medical Officer of Intellia Therapeutics, reports the vesting of restricted stock units and subsequent conversion to common stock.

Laura Sepp-Lorenzino, EVP and Chief Scientific Officer of Intellia Therapeutics, reports the acquisition of 3,500 shares of common stock and related restricted stock units.

John Leonard, CEO of Intellia Therapeutics, reports the vesting of restricted stock units and related transactions.

Michael P. Dube, VP and Chief Accounting Officer of Intellia Therapeutics, sold 2,012 shares of common stock to cover tax obligations arising from the vesting of RSUs.

EVP and CFO of Intellia Therapeutics, Edward Dulac III, reports acquisition of restricted stock units and stock options.

Eliana Clark, EVP and Chief Technical Officer of Intellia Therapeutics, sold 405 shares of common stock at a price of $22.93 on July 1, 2024.

Michael P. Dube, VP, PAO and Interim PFO of Intellia Therapeutics, acquired 17,801 shares of common stock on July 1, 2024, through a restricted stock unit grant.

Frank Verwiel, a director at Intellia Therapeutics, sold 1,505 shares of common stock at $25 per share on June 17, 2024, under a pre-arranged 10b5-1 trading plan.

Director Brian Goff reports acquisition of 15,409 shares of common stock and 22,297 stock options in Intellia Therapeutics.